Multicentre, non-interventional study to assess the profile of patients with uncontrolled rhinitis prescribed a novel formulation of azelastine hydrochloride and fluticasone propionate in a single spray in routine clinical practice in the UK by Scadding, G. et al.
Multicentre, non-interventional study
to assess the proﬁle of patients with
uncontrolled rhinitis prescribed a novel
formulation of azelastine hydrochloride
and ﬂuticasone propionate in a
single spray in routine clinical practice
in the UK
Glenis Scadding,1 David Price,2,3 Tariq El-Shanawany,4 Shahzada Ahmed,5
Jaydip Ray,6 Ravishankar Sargur,7 Nirmal Kumar8
To cite: Scadding G, Price D,
El-Shanawany T, et al.
Multicentre, non-
interventional study to assess
the profile of patients with
uncontrolled rhinitis
prescribed a novel
formulation of azelastine
hydrochloride and fluticasone
propionate in a single spray
in routine clinical practice in
the UK. BMJ Open 2017;7:
e014777. doi:10.1136/
bmjopen-2016-014777
▸ Prepublication history for
this paper is available online.
To view these files please
visit the journal online
(http://dx.doi.org/10.1136/
bmjopen-2016-014777).
Received 24 October 2016
Revised 15 February 2017
Accepted 27 February 2017
For numbered affiliations see
end of article.
Correspondence to
Dr Glenis Scadding;
g.scadding@ucl.ac.uk
ABSTRACT
Objective: The aims of this study were (1) to
characterise the type of patient prescribed MP-AzeFlu
(Dymista, a novel formulation of azelastine
hydrochloride, fluticasone propionate and excipients
in a single spray) in real life in the UK and physicians’
reasons for prescribing it and (2) to quantify the
personal and societal burden of allergic rhinitis (AR)
in the UK prior to MP-AzeFlu prescription.
Design, setting and participants: This
multicentre, non-interventional study enrolled patients
(n=193) with moderate-to-severe AR and acute
symptoms who were eligible to receive treatment with
MP-AzeFlu according to its licensed indications.
Information was gathered on patient demographics,
AR history and symptom severity, symptomatology
and AR treatments in the previous calendar year
(prior to MP-AzeFlu prescription). Physicians also
recorded the number of previous AR visits, specific
reasons for these visits and their reason for
prescribing MP-AzeFlu.
Results: Most patients had seasonal AR either alone
(10.4%) or in combination with perennial AR
(35.2%), but many had AR of unknown origin
(35.8%). Prior to MP-AzeFlu prescription, patients
reported troublesome symptoms (78.2%) and sleep
disturbance (64.8%), with congestion considered the
most bothersome (54.4%) and ocular symptoms
reported by 68.4% of patients. The most frequent
reason for MP-AzeFlu prescription was that other
therapies were not sufficient in the past (78.8%) or
not sufficient to treat acute symptoms (16.1%).
79.3% of patients reported using ≥2 AR therapies in
the past year. An average of 1.6 (SD 1.9) doctor visits
due to AR were reported prior to MP-AzeFlu
prescription.
Conclusions: In the UK, MP-AzeFlu was prescribed
for individuals (≥12 years) with moderate/severe AR
irrespective of (1) previous AR treatment (mono or
multiple), (2) previous or likely treatment failure, (3)
phenotype, (4) number of previous physician visits
for AR and (5) for the relief of both acute symptoms
and in anticipation of allergen exposure.
INTRODUCTION
One in four individuals in the UK has aller-
gic rhinitis (AR),1 2 yet this disease continues
to be underestimated, both in terms of its
impact on individuals and their families,3 4
as well as its cost to the economy. When
symptomatic, patients feel the impact of AR
on all areas of their daily lives, at home,
socially and at work/school.5–7 Indeed, in
Strengths and limitations of this study
▪ Sufficiently large patient numbers to draw
general conclusion on use of MP-AzeFlu in
routine clinical practice in the UK.
▪ Low amount of missing data.
▪ Real-life data obtained from daily practice high-
lighting the burden of allergic rhinitis in the UK
and the type of patient prescribed MP-AzeFlu.
▪ Relates type of patient prescribed MP-AzeFlu
with the labelled indication, thus providing
sound estimates for relevant subgroups from a
socioeconomic perspective.
▪ For such single-arm epidemiological research,
standard bias limiting methods (blinding, ran-
domisation) could not be applied.
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the UK, children with symptomatic AR are more likely
to unexpectedly drop an examination grade during
summer tests than their non-AR counterparts, and are
even more at risk of so doing if taking sedating antihista-
mines.8 Poorly controlled AR also has a negative impact
on asthma control, equivalent to that induced by
smoking.9 While the direct costs (eg, drug costs) asso-
ciated with AR are relatively low, the indirect costs due
to absenteeism and presenteeism are disproportionately
large, estimated at £1.4 billion/year in the UK alone.10
The burden of AR and the importance of
achieving disease control has now been recognised
both by the European Academy of Allergy and Clinical
Immunology11 and at the European Union (EU)
level.12 13 Provision of more effective and fast acting AR
treatments proven to achieve guideline-deﬁned control
in real life should help reduce the burden of disease
and associated management costs.14
MP-AzeFlu (Mylan Inc, Canonsburg, PA, USA) com-
prises a novel formulation containing an intranasal anti-
histamine (azelastine hydrochloride), an intranasal
corticosteroid (INS), ﬂuticasone propionate (FP) and
excipients delivered in a single spray. It has been
approved for use in the UK since January 2013, indi-
cated for the relief of symptoms of moderate-to-severe
seasonal AR (SAR) and perennial AR (PAR) if mono-
therapy with either intranasal antihistamine or gluco-
corticoid is not considered sufﬁcient.15 In a randomised
controlled clinical trial (RCT) setting, MP-AzeFlu pro-
vided twice the overall nasal and ocular symptom relief
as FP or azelastine monotherapy, and provided faster
complete (or near-complete) relief in more patients.16
Patients treated with MP-AzeFlu in real-life settings in
Germany, Sweden, Denmark, Norway and Romania
experienced rapid and sustained symptom control, with
one in two patients reporting that their AR was well con-
trolled after 3 days.17 In those studies, control was
assessed using the a simple visual analogue scale (VAS)
score, as endorsed by MACVIA-ARIA (Contre les
Maladie Chronique pour un Vieillissement Actif-Allergic
Rhinitis and its Impact on Asthma) and incorporated
into the updated guideline, called AR clinical decision
support system (CDSS).14 On average, patients treated
with MP-AzeFlu crossed the well-controlled VAS score
cut-off (ie, 5/10 cm) prior to day 3, irrespective of
disease severity, phenotype (SAR, PAR, SAR+PAR and
unknown) or previous treatment (with monotherapy or
multiple therapies).17
Characteristics of patients who received MP-AzeFlu in
an RCT setting are well established, due to strict inclu-
sion/exclusion criteria applied to ensure a homoge-
neous patient population and low external variability.18
However, detailed characteristics of those patients pre-
scribed MP-AzeFlu in routine clinical practice are
unknown. The aim of this study was to (1) characterise
the type of patient prescribed MP-AzeFlu in real life in
the UK and physicians’ reasons for prescribing it; (2)
quantify the burden of AR prior to MP-AzeFlu
prescription; and (3) describe AR treatment patterns for
these patients prior to MP-AzeFlu use in the UK. The
effectiveness of MP-AzeFlu in a real-life pan-European
clinical setting has already been established.17
METHODS
Study design
This was a multicentre, non-interventional study con-
ducted in the UK between October 2013 and May 2014,
as part of a larger Europe-wide study of similar design.
During the study, patients were treated with MP-AzeFlu
(one spray in each nostril twice daily). MP-AzeFlu is indi-
cated for the relief of symptoms of moderate-to-severe
SAR and PAR if monotherapy with either intranasal anti-
histamine or glucocorticoid is not considered sufﬁ-
cient.15 The study was performed in line with the
current UK laws and guidelines. The study was regis-
tered at the European Network of Centres for
Pharmacoepidemiology and Pharmacovigilance.
Patients
Patients were eligible for inclusion into the study if they
were aged ≥12 years, had a documented diagnosis of
moderate-to-severe SAR or PAR and for whom mono-
therapy with either intranasal antihistamine or gluco-
corticoid were not considered sufﬁcient.15 Patients were
required to have acute AR symptoms on the study inclu-
sion day. Patients with SAR were deﬁned as those with a
documented allergy to at least one pollen allergen (ie,
spring, summer and/or autumn pollen) but no non-
pollen allergens. Patients with PAR were those with a
documented allergy to at least one non-pollen allergen
(ie, dust mites, pet dander and/or mould) but no
pollen allergens. Patients with both SAR+PAR had docu-
mented allergy to at least one pollen and at least one
non-pollen allergen. Rhinitis of unknown origin was
deﬁned as allergy to other or unknown allergens (ie,
not one of the allergens listed above) or unknown aller-
gens (ie, rhinitis indicated from history but no speciﬁc
IgE data).
Patients were excluded if they had hypersensitivity to
azelastine hydrochloride, FP or any MP-AzeFlu excipi-
ents. There were no restrictions regarding concomitant
treatments, apart from ritonavir, which was to be
avoided. Female patients were excluded if they were
pregnant or breast feeding. All patients provided written
informed consent prior to their participation in the
study. If patients were below 16 years old, their caregiver
also provided written informed consent.
Physicians
Physicians who were usually involved in AR management
participated in this study and included secondary care
ear-nose-and-throat (ENT) specialists, immunologists
and allergists. These physicians were identiﬁed by an
independent agency (pH Associates, UK). Each phys-
ician could enrol up to 20 patients. The decision
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whether to include a patient in the study was made by
the physician independently from and after the decision
to prescribe MP-AzeFlu had been made.
MP-AzeFlu use in routine clinical practice
Information on patient demographics, clinical symptoms
and AR treatments in the previous calendar year (prior
to MP-AzeFlu prescription) was documented by physi-
cians. Physicians also recorded information on type of
AR, number of visits in the current calendar year due to
AR, predominant symptoms and ARIA-deﬁned AR sever-
ity. The reason for the patient’s visit (acute AR symp-
toms, expected allergen exposure in near future or
other) and the reason for prescribing MP-AzeFlu (other
therapies were not sufﬁcient in the past, other therapies
are not considered to be sufﬁcient to treat acute symp-
toms or other) was documented by the physician. All
data were recorded by physicians in a prespeciﬁed
English language electronic case report from (Trium
Analysis Online GmbH) based on the investigators’
patient ﬁles and on information obtained at the patient
visit.
Statistics
This study included 193 patients with AR, which was
deemed sufﬁcient to provide insight into use of
MP-AzeFlu in routine clinical practice in the UK.
Analyses were conducted on the safety population,
deﬁned as all patients who were treated at least once
with MP-AzeFlu and whose physician provided an elec-
tronic signature to conﬁrm data accuracy. All data were
reported with descriptive statistics. Categorical data were
described in terms of frequency and as percentage of
patients. Continuous data were described as mean and
SD. Analyses were performed by the Contract Research
Organisation, Syneed Medidata GmbH, with SAS V.9.1.3.
RESULTS
Patient disposition
The study was conducted in 15 study centres in the UK
who enrolled 195 patients. Of these, 2 patients were
excluded from data analysis due to unconﬁrmed data
documentation, leaving 193 conﬁrmed patients in the
safety population.
Patient demographics and baseline characteristics
A summary of patient demographics and baseline clin-
ical characteristics is presented in table 1. There were
slightly more women than men in the safety population.
The mean (SD) age of the study population was 37.6
(16.9) years, with most of the patients aged 18–65 years.
Almost half of patients had SAR, either alone or in com-
bination with PAR. A relatively high proportion of
patients had rhinitis with aetiology of unknown origin
(table 1). The vast majority of patients had conﬁrmed
ARIA-deﬁned moderate-to-severe disease. AR symptoms
were troublesome to patients, negatively impacting
sleep, daily activities, leisure and/or sport and school/
work. Nasal congestion was by far the most common pre-
dominant symptom. Ocular symptoms were present in
over two-thirds of patients (table 1).
Physician visits
In the current calendar year, the mean (SD) number of
physician visits due to AR was 1.6 (1.9). In total, 62.7%
(n=121) of patients had visited their physician at least
once before inclusion into the study in the current cal-
endar year due to their AR (ﬁgure 1); with most attend-
ing once or twice before. However, 23.8% of patients
(n=46) had made three or more visits prior to the
current visit (ﬁgure 1).
Reasons for patient visit and MP-AzeFlu prescription
MP-AzeFlu was prescribed according to its licensed indi-
cation. The most frequent reasons for the physician visit
were ‘acute AR symptoms’ (n=142; 73.6%), ‘expected
allergen exposure in the near future’ (n=21; 10.9%) and
‘other’ (n=37; 19.2%). The most frequent reason for
prescribing MP-AzeFlu was that ‘other therapies were
not sufﬁcient in the past’. For the remaining patients,
other reasons were cited, including ‘other therapies
were not considered sufﬁcient to treat acute symptoms’
(ﬁgure 2).
Table 1 Patient demographics and baseline clinical
characteristics (N=193)
Characteristic n (%)
Gender
Female 107 (55.4)
Age, years
12–17 22 (11.4)
18–65 155 (80.3)
>65 16 (8.3)
Duration of rhinitis,* year (mean (SD)) 8.5 (9.4)
Type of rhinitis
SAR 20 (10.4)
PAR 36 (18.6)
SAR+PAR 68 (35.2)
Unknown origin 69 (35.8)
Severity of AR criteria†
Troublesome symptoms 151 (78.2)
Sleep disturbance 125 (64.8)
Impairment of daily activities/leisure/sport 109 (56.5)
Impairment of school/work 93 (48.2)
At least one criteria 175 (90.7)
Predominant symptoms
Nasal congestion 105 (54.4)
Rhinorrhoea 26 (13.5)
Sneezing 20 (10.4)
Nasal itching 10 (5.2)
Unknown 32 (16.6)
Concomitant ocular symptoms 132 (68.4)
*N=136.
†Moderate/severe AR if at least one criterion was met.
AR, allergic rhinitis; PAR, perennial allergic rhinitis; SAR, seasonal
allergic rhinitis.
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AR treatments in the last year
The majority of patients had received or used at least one
AR therapy, either with prescription or over the counter,
prior to MP-AzeFlu prescription (table 2). The AR medica-
tions most frequently used in the previous year were INS,
oral antihistamines and oral/intranasal decongestants.
Eye drops, either antihistamine or mast cell stabiliser use,
was reported by over a quarter of patients. Systemic cor-
ticosteroid use was noted for quite a high proportion of
patients (table 2). The majority of patients reported using
multiple AR treatments in the previous year, prior to
MP-AzeFlu use; dual AR therapy was most commonly
reported, but many also used triple and even quadruple
AR therapies (ﬁgure 3). A total of 25 patients (13.0%)
reported previously using ﬁve or more AR treatments
prior to MP-AzeFlu prescription. Seven patients (3.6%)
stated that they were undergoing immunotherapy at the
time of the inclusion visit and 1 (0.5%) had received an
immunotherapy course in the previous calendar year.
DISCUSSION
This study represents a valuable addition to the AR knowl-
edge base for several reasons. First, it provides important
epidemiological data on the type of patient with AR pre-
senting to secondary care allergy clinics in the UK, as well
as information on AR history and symptomatology of
those who received MP-AzeFlu. Second, it conﬁrms the
enormous (and frequently underestimated)4 burden
imposed by uncontrolled AR symptoms on patients’ lives.
Third, it provides information on AR treatment pattern in
the UK (prior to MP-AzeFlu prescription) and the short-
comings of commonly used treatments in providing
symptom control. It also explores the high socioeconomic
burden imposed by AR, as seen through medication usage
and number of doctor visits for AR. Finally, this study
details how the indication for MP-AzeFlu,15 a relatively
new addition to the AR armoury, was interpreted by pre-
scribing physicians in secondary and tertiary care during
the ﬁrst months of its introduction and use in the UK.
Figure 1 Number of previous
physician visits for AR in the
current calendar year prior to
prescribing MP-AzeFlu. N=193
patients with moderate-to-severe
AR attending routine clinical
practice in the UK. AR, allergic
rhinitis.
Figure 2 Most frequent reasons
reported by physicians for
prescribing MP-AzeFlu to patients
with moderate-to-severe allergic
rhinitis (n=193) attending routine
clinical practice in the UK. Tx,
treatment.
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Physicians who took part in this non-interventional
study (ie, allergists, ENT specialists and immunologists)
prescribed MP-AzeFlu to adolescents, adults and elderly
patients with moderate/severe AR (ie, ≥1 ARIA severity
criteria)19 in line with its indication.15 It was prescribed
to those patients for whom other AR therapies were not
considered sufﬁcient, and also to those for whom other
therapy had not worked in the past. This decision
depends very much on physician and patient preference;
that is, the preference for rapid AR symptom control
straight away with the most effective pharmacological
treatment option, or a gradual therapy step up until
control has been achieved. MP-AzeFlu was prescribed
for the treatment of acute symptoms, and also prophy-
lactically in the anticipation of allergen exposure in the
near future. It was prescribed for patients with SAR,
PAR, both SAR and PAR and for those whose AR aeti-
ology was not deﬁned, which represented about
one-third of patients in the current study. This unknown
group is likely quite heterogeneous in nature, and could
include those with non-AR, or local AR, as well as those
with SAR or PAR of unknown allergen or allergen not
listed. Finally, MP-AzeFlu was prescribed for patients pre-
viously on AR monotherapy and for those attending
clinic for the ﬁrst time in the season. It was also pre-
scribed for patients with more complicated disease who
had attended many times in the past year for AR, and
for those on multiple therapies or immunotherapy.
Although MACVIA ARIA clearly recommends
MP-AzeFlu for the treatment of intermittent and persist-
ent AR,14 a signiﬁcant proportion of patients who may
beneﬁt from this treatment in the UK have not received
it. The need for wider awareness and use of MP-AzeFlu
in the UK (particularly in primary care) is shown by the
fact that prior to MP-AzeFlu prescription the majority of
patients reported troublesome symptoms, sleep disturb-
ance and impairment of their daily activities, with almost
half acknowledging a negative impact of their AR symp-
toms on performance at work or school. The negative
impact of AR symptoms on daily activities has previously
been shown to be greater for patients with AR than
those with diabetes mellitus or hypertension.20 Others
have shown that living with symptomatic AR can impair
school performance,8 impair driving ability to the
same extent as a blood alcohol level of 0.05%,21
reduce work productivity10 22 and induce absentee-
ism.10 The latter two carry a hefty price tag, with absen-
teeism due to AR estimated to cost the UK economy
£1.14 billion/year10 and the cost of lost productivity
due to AR thought to exceed that of chronic heart
Table 2 AR treatments in the past year (N=193)
AR treatments (multiple entries possible) n (%)
Intranasal corticosteroid 162 (83.9)
Oral antihistamine 128 (66.3)
Intranasal decongestant 47 (24.4)
Oral decongestant 41 (21.2)
Systemic corticosteroid 36 (18.7)
Intranasal antihistamine 31 (16.1)
Ocular antihistamine 31 (16.1)
Ocular mast cell stabiliser 23 (11.9)
Oral leucotriene receptor antagonist 12 (6.2)
Intranasal mast cell stabiliser 1 (0.5)
Any other 11 (5.7)
Unknown 8 (4.2)
None 3 (1.6)
Immunotherapy (in past or ongoing) 8 (4.1)
Multiple therapies (excluding immunotherapy) 153 (79.3)
AR, allergic rhinitis.
Figure 3 Number of AR treatments (prescription and over the counter) used in the last calendar year by patients with AR with
moderate-to-severe AR (n=193) attending routine clinical practice in the UK. AR, allergic rhinitis.
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disease, asthma, diabetes, hypertension and respiratory
infections combined!22
The results of this study also show that the most com-
monly prescribed AR treatments in the UK do not
provide adequate symptom relief for many patients,
further endorsing the need for MP-AzeFlu. Prescribing
physicians considered that other therapies were not sufﬁ-
cient in the past for 66.4% of patients and would not
provide adequate symptom relief for 34.5% of patients.
Most patients prescribed MP-AzeFlu had previously been
treated with INS and/or oral antihistamines. Inadequacy
of previous AR treatments was also evident from the
high symptomatic burden on treatment reported by
patients, the high degree of polypharmacy noted
(79.3%) and the high incidence of use of systemic corti-
costeroids (18.7%) and decongestants (45.6%). The
former are rarely indicated for the management of rhin-
itis (except for severe obstruction or short-term rescue
use),23 while long-term use of the latter has been asso-
ciated with rhinitis medicamentosa. A previous survey
conducted in the UK also revealed that patients retained
a high nasal and ocular symptom burden despite treat-
ment with monotherapy or multiple AR therapies.10
Furthermore, a retrospective observational study with
data from the Optimum Patient Care Research Database
showed that in the UK monotherapy with antihistamines
or INS provided insufﬁcient symptom relief for about
20% of patients with SAR.24 AR monotherapy was pre-
scribed ﬁrst for most patients, but by season end 45% of
patients with SAR had received multiple therapy, a prac-
tice which is not recommended by ARIA19 due to insufﬁ-
cient evidence.25 26 The current British Society for
Allergy and Clinical Immunology (BSACI) UK guide-
lines suggest that additional therapies should be consid-
ered for brief-targeted symptom relief only.23
The concept of achieving symptom relief (ie, reduction
in symptom severity) has been now superseded by the
concept of achieving symptom control.14 A simple VAS is
recommended by MACVIA ARIA as the new language of
AR control.12 The VAS has been used extensively in the
ﬁeld of AR to assess symptom severity27 and treatment
effectiveness,28 to deﬁne phenotypes, such as severe
chronic upper airway disease,29 and to deﬁne clinically
relevant effect.30 A VAS score of 5/10 cm is the cut-off
used to deﬁne control and guide treatment decisions as
part of an updated ARIA AR treatment algorithm called
the AR CDSS.14 It has also been incorporated into an app
(Allergy Diary) to empower patients to take control of
their own AR.12 Data obtained from several countries
(Germany, Sweden, Norway, Denmark and Romania)
which gathered real-life data as part of a multinational
pan-European study have shown that on average patients
treated with MP-AzeFlu achieve this AR CDSS VAS score
cut-off (ie, 5 cm) prior to day 3, with one in two patients
perceiving their AR as well controlled at that time
point.31–35 The UK data presented here are taken from
the same multinational pan-European study. Although,
effectiveness data were not recorded in the UK arm,
results are expected to be consistent with those found in
other countries with similar patient characteristics.
MP-AzeFlu has the potential to reduce costs associated
with managing AR in the UK, by reducing multiple
prescriptions, number of doctor visits, referrals to second-
ary care and potentially reducing the number of patients
referred for allergen-speciﬁc immunotherapy (AIT); sup-
porting UK National Health Service (NHS) cost-saving
initiatives to manage more chronic conditions in the
primary care setting.
The limitations of this study are those typically asso-
ciated with non-interventional, observational data sets as
the standard methods of blinding and randomisation
cannot be applied. Thus, confounding can never safely
be ruled out. Another limitation is that our study
included no investigation of the effectiveness of
MP-AzeFlu, and there was no direct head-to-head com-
parison of MP-AzeFlu with other AR treatments.
However, the effectiveness of MP-AzeFlu has been
demonstrated in real-life studies conducted in other
countries.17 The strength of the evidence is derived
from the inclusion of a sufﬁciently large patient popula-
tion to draw general conclusion on use and safety of
MP-AzeFlu in routine clinical practice in UK. The type
of patient prescribed MP-AzeFlu in the UK was consist-
ent with the patient proﬁle identiﬁed in other countries
including Germany, Sweden, Denmark and Romania,
supporting the generalisability of our data to a wider
pan-European population. In the pooled analysis for all
countries as well as for the presented UK data, the study
data were complete for most demographic variables;
therefore, missing data are not considered as a potential
source of bias for the study results.
In conclusion, the symptomatic burden of AR remains
high for many patients in the UK, who live with uncon-
trolled disease, despite treatment with monotherapy and
multiple therapies and repeat doctor visits. In the UK,
MP-AzeFlu was prescribed for individuals (≥12 years)
with moderate/severe AR irrespective of (1) previous AR
treatment (mono or multiple), (2) previous or likely
treatment failure, (3) phenotype, (4) number of previ-
ous physician visits for AR and (5) for the relief of both
acute symptoms and in anticipation of allergen expos-
ure. A more effective treatment option, like MP-AzeFlu,
with established superiority over INS and antihistamine
monotherapy, should improve AR control.
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